GIP and Fabry disease: The mechanisms demonstrated in preclinical and clinical studies, combined with evidence from key clinical trials, suggest GLP-1 agonists and GIP/GLP-1 agonists could address both conventional cardiovascular risk factors and FD-specific pathophysiology.